Tirapazamine (Synonyms: 替拉扎明; SR259075; SR4233; Win59075; SML 0552; SR 259075; Tirazone)

目录号: HY-13767 纯度: 99.73%: FAQs
Data Sheet SDS COA 产品使用指南

摩尔计算器

Tirapazamine (SR259075) 是一种抗癌剂，对实体瘤中的缺氧细胞具有选择性细胞毒性，从而诱导 DNA 中的单链和双链断裂，碱基损伤和细胞死亡。Tirapazamine (SR259075) 是一种抗癌和生物还原剂。Tirapazamine (SR259075) 能增强电离辐射对缺氧细胞的细胞毒性作用。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Tirapazamine Chemical Structure

CAS No. : 27314-97-2

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥726	In-stock
50 mg	￥660	In-stock
100 mg	￥1116	In-stock
200 mg	￥1860	In-stock
500 mg		询价
1 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

MCE 顾客使用本产品发表的 10 篇科研文献

Tirapazamine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性
纯度 & 产品资料
参考文献

生物活性

Tirapazamine (SR259075) is an anticancer agent that shows selective cytotoxicity for hypoxic cells in solid tumors, thereby inducing single-and double-strand breaks in DNA, base damage, and cell death. Tirapazamine is an anticancer and bioreductive agent.Tirapazamine (SR259075) can enhance the cytotoxic effects of ionizing radiation in hypoxic cells^[1]^[2].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 50 μM Compound: TPZ	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
A549	IC₅₀	1.93 μM Compound: TPZ	Cytotoxicity against human A549 cells for 72 hrs under hypoxic condition by MTT assay Cytotoxicity against human A549 cells for 72 hrs under hypoxic condition by MTT assay	[PMID: 21281992]
A549	GI₅₀	6.8 μM Compound: Tirapazamine	Cytotoxicity against human A549 cells incubated for 4 hrs in anoxic condition followed by oxic exposure for 48 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells incubated for 4 hrs in anoxic condition followed by oxic exposure for 48 hrs by sulforhodamine B assay	[PMID: 32196334]
A549	IC₅₀	6.9 μM Compound: TPZ	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
A549	GI₅₀	63 μM Compound: Tirapazamine	Cytotoxicity against human A549 cells incubated for 52 hrs in oxic condition by sulforhodamine B assay Cytotoxicity against human A549 cells incubated for 52 hrs in oxic condition by sulforhodamine B assay	[PMID: 32196334]
A549	IC₅₀	7.43 μM Compound: TPZ	Cytotoxicity against human A549 cells for 72 hrs under normoxic condition by MTT assay Cytotoxicity against human A549 cells for 72 hrs under normoxic condition by MTT assay	[PMID: 21281992]
COLO 205	IC₅₀	47.7 μM Compound: Tirapazamine	Cytotoxicity against human COLO205 cells measured after 48 hrs under hypoxic condition by CCK8 assay Cytotoxicity against human COLO205 cells measured after 48 hrs under hypoxic condition by CCK8 assay	[PMID: 27140429]
H9c2	EC₅₀	> 100 μM Compound: 10; TPZ	Cytotoxicity against rat H9c2 cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by Hoechst 33342 staining based microscopic analysis Cytotoxicity against rat H9c2 cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by Hoechst 33342 staining based microscopic analysis	[PMID: 34124675]
HCT-116	IC₅₀	11.9 μM Compound: Tirapazamine	Cytotoxicity against human HCT116 cells measured after 48 hrs under hypoxic condition by CCK8 assay Cytotoxicity against human HCT116 cells measured after 48 hrs under hypoxic condition by CCK8 assay	[PMID: 27140429]
HCT-116	IC₅₀	72.7 μM Compound: Tirapazamine	Cytotoxicity against human HCT116 cells measured after 18 hrs under hypoxic condition by CCK8 assay Cytotoxicity against human HCT116 cells measured after 18 hrs under hypoxic condition by CCK8 assay	[PMID: 27140429]
HepG2	IC₅₀	19.1 μM Compound: TPZ	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 16777409]
HepG2	IC₅₀	56.6 μg/mL Compound: TPZ	Growth inhibition of human HepG2 cells after 48 hrs by SRB assay Growth inhibition of human HepG2 cells after 48 hrs by SRB assay	[PMID: 20236735]
HL-60	IC₅₀	16.1 μM Compound: TPZ	Cytotoxicity against human HL60 cells in normoxia after 48 hrs Cytotoxicity against human HL60 cells in normoxia after 48 hrs	[PMID: 16777409]
HL-60	IC₅₀	2.31 μM Compound: TPZ	Ratio of cytotoxicity against human HL60 cells in normoxia to hypoxia after 48 hrs Ratio of cytotoxicity against human HL60 cells in normoxia to hypoxia after 48 hrs	[PMID: 16777409]
HL-60	IC₅₀	7 μM Compound: TPZ	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 16777409]
HL-60	IC₅₀	7 μM Compound: TPZ	Cytotoxicity against human HL60 cells in hypoxia after 48 hrs Cytotoxicity against human HL60 cells in hypoxia after 48 hrs	[PMID: 16777409]
HT-29	IC₅₀	> 50 μM Compound: TPZ	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under normoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
HT-29	IC₅₀	> 50 μM Compound: TPZ	Cytotoxicity against human HT-29 cells after 72 hrs under normoxia conditions by SRB assay Cytotoxicity against human HT-29 cells after 72 hrs under normoxia conditions by SRB assay	[PMID: 25462282]
HT-29	IC₅₀	387 μM Compound: TPZ	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth under normoxia condition by SRB assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth under normoxia condition by SRB assay	[PMID: 28851503]
HT-29	IC₅₀	5.1 μM Compound: 1, TPZ	Cytotoxicity against human HT29 cells under hypoxic conditions after 4 hrs Cytotoxicity against human HT29 cells under hypoxic conditions after 4 hrs	[PMID: 18001018]
HT-29	IC₅₀	5.1 μM Compound: 1, TPZ	Cytotoxicity against human HT-29 cells after 4 hrs under strict hypoxic condition Cytotoxicity against human HT-29 cells after 4 hrs under strict hypoxic condition	[PMID: 18847185]
HT-29	IC₅₀	6.2 μM Compound: TPZ	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth under hypoxia condition by SRB assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth under hypoxia condition by SRB assay	[PMID: 28851503]
HT-29	IC₅₀	9.45 μM Compound: TPZ	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation under hypoxia conditions after 72 hrs by SRB assay	[PMID: 25468044]
HT-29	IC₅₀	9.45 μM Compound: TPZ	Cytotoxicity against human HT-29 cells after 72 hrs under hypoxia conditions by SRB assay Cytotoxicity against human HT-29 cells after 72 hrs under hypoxia conditions by SRB assay	[PMID: 25462282]
K562	IC₅₀	1.81 μM Compound: TPZ	Cytotoxicity against human K562 cells for 72 hrs under hypoxic condition by MTT assay Cytotoxicity against human K562 cells for 72 hrs under hypoxic condition by MTT assay	[PMID: 21281992]
K562	IC₅₀	19.41 μM Compound: TPZ	Cytotoxicity against human K562 cells for 72 hrs under normoxic condition by MTT assay Cytotoxicity against human K562 cells for 72 hrs under normoxic condition by MTT assay	[PMID: 21281992]
K562	IC₅₀	5.2 μM Compound: TPZ	Cytotoxicity against human K562 cells after 48 hrs by MTT assay Cytotoxicity against human K562 cells after 48 hrs by MTT assay	[PMID: 16777409]
KB	IC₅₀	18.71 μM Compound: TPZ	Cytotoxicity against human KB cells for 72 hrs under hypoxic condition by MTT assay Cytotoxicity against human KB cells for 72 hrs under hypoxic condition by MTT assay	[PMID: 21281992]
KB	IC₅₀	6.29 μM Compound: TPZ	Cytotoxicity against human KB cells for 72 hrs under normoxic condition by MTT assay Cytotoxicity against human KB cells for 72 hrs under normoxic condition by MTT assay	[PMID: 21281992]
MDA-MB-468	IC₅₀	1.304 μM Compound: Tirapazamine	Cytotoxicity against human MDA-MB-468 cells incubated for 4 hrs under hypoxic condition followed by compound washout and measured after 5 days by SRB assay Cytotoxicity against human MDA-MB-468 cells incubated for 4 hrs under hypoxic condition followed by compound washout and measured after 5 days by SRB assay	[PMID: 30885680]
MDA-MB-468	IC₅₀	105.2 μM Compound: Tirapazamine	Cytotoxicity against human MDA-MB-468 cells incubated for 4 hrs under aerobic condition followed by compound washout and measured after 5 days by SRB assay Cytotoxicity against human MDA-MB-468 cells incubated for 4 hrs under aerobic condition followed by compound washout and measured after 5 days by SRB assay	[PMID: 30885680]
MDCK	IC₅₀	< 50 μM Compound: Tirapazamine	Cytotoxicity against carbonic anhydrase 9 knockdown MDCK cells assessed as reduction in cell viability after 2 hrs under hypoxic condition by Alamar blue assay Cytotoxicity against carbonic anhydrase 9 knockdown MDCK cells assessed as reduction in cell viability after 2 hrs under hypoxic condition by Alamar blue assay	[PMID: 27823879]
MDCK	IC₅₀	> 300 μM Compound: Tirapazamine	Cytotoxicity against carbonic anhydrase 9 knockdown MDCK cells assessed as reduction in cell viability preincubated for 2 hrs followed by 72 hrs incubation under normoxic condition by Alamar blue assay Cytotoxicity against carbonic anhydrase 9 knockdown MDCK cells assessed as reduction in cell viability preincubated for 2 hrs followed by 72 hrs incubation under normoxic condition by Alamar blue assay	[PMID: 27823879]
MDCK	IC₅₀	> 300 μM Compound: Tirapazamine	Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability preincubated for 2 hrs followed by 72 hrs incubation under normoxic condition by Alamar blue assay Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability preincubated for 2 hrs followed by 72 hrs incubation under normoxic condition by Alamar blue assay	[PMID: 27823879]
MDCK	IC₅₀	95 μM Compound: Tirapazamine	Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability after 2 hrs under hypoxic condition by Alamar blue assay Cytotoxicity against MDCK cells expressing carbonic anhydrase 9 assessed as reduction in cell viability after 2 hrs under hypoxic condition by Alamar blue assay	[PMID: 27823879]
MOLM-13	EC₅₀	22 μM Compound: 10; TPZ	Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 24 hrs under 2% O2 condition by Hoechst 33342 staining based microscopic analysis Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 24 hrs under 2% O2 condition by Hoechst 33342 staining based microscopic analysis	[PMID: 34124675]
MOLM-13	EC₅₀	22 μM Compound: 4; TPZ	Antiproliferative activity against human MOLM13 cells after 24 hrs under 2% O2 condition by Hoechst 33342 staining-based UV-microscopic analysis Antiproliferative activity against human MOLM13 cells after 24 hrs under 2% O2 condition by Hoechst 33342 staining-based UV-microscopic analysis	[PMID: 28284865]
MOLM-13	EC₅₀	95 μM Compound: 10; TPZ	Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by Hoechst 33342 staining based microscopic analysis Cytotoxicity against human MOLM13 cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by Hoechst 33342 staining based microscopic analysis	[PMID: 34124675]
MOLM-13	EC₅₀	95 μM Compound: 4; TPZ	Antiproliferative activity against human MOLM13 cells after 24 hrs under 19% O2 condition by Hoechst 33342 staining-based UV-microscopic analysis Antiproliferative activity against human MOLM13 cells after 24 hrs under 19% O2 condition by Hoechst 33342 staining-based UV-microscopic analysis	[PMID: 28284865]
MOLT-4	IC₅₀	15.8 μM Compound: TPZ	Cytotoxicity against human Molt4 cells in normoxia after 48 hrs Cytotoxicity against human Molt4 cells in normoxia after 48 hrs	[PMID: 16777409]
MOLT-4	IC₅₀	3.43 μM Compound: TPZ	Ratio of cytotoxicity against human Molt4 cells in normoxia to hypoxia after 48 hrs Ratio of cytotoxicity against human Molt4 cells in normoxia to hypoxia after 48 hrs	[PMID: 16777409]
MOLT-4	IC₅₀	4.6 μM Compound: TPZ	Cytotoxicity against human Molt4 cells after 48 hrs by MTT assay Cytotoxicity against human Molt4 cells after 48 hrs by MTT assay	[PMID: 16777409]
MOLT-4	IC₅₀	4.6 μM Compound: TPZ	Cytotoxicity against human Molt4 cells in hypoxia after 48 hrs Cytotoxicity against human Molt4 cells in hypoxia after 48 hrs	[PMID: 16777409]
NCI-H460	IC₅₀	> 100 μM Compound: tirapazamine	Cytotoxicity against human H460 cells under normoxic condition after 2 hrs by Alamar blue staining assay Cytotoxicity against human H460 cells under normoxic condition after 2 hrs by Alamar blue staining assay	[PMID: 18257544]
NCI-H460	IC₅₀	11 μM Compound: tirapazamine	Cytotoxicity against human H460 cells under hypoxic condition after 2 hrs by Alamar blue staining assay Cytotoxicity against human H460 cells under hypoxic condition after 2 hrs by Alamar blue staining assay	[PMID: 18257544]
NRK	EC₅₀	> 100 μM Compound: 10; TPZ	Cytotoxicity against rat NRK cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by Hoechst 33342 staining based microscopic analysis Cytotoxicity against rat NRK cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by Hoechst 33342 staining based microscopic analysis	[PMID: 34124675]
NRK	EC₅₀	35 μM Compound: 10; TPZ	Cytotoxicity against rat NRK cells assessed as reduction in cell viability incubated for 24 hrs under 2% O2 condition by Hoechst 33342 staining based microscopic analysis Cytotoxicity against rat NRK cells assessed as reduction in cell viability incubated for 24 hrs under 2% O2 condition by Hoechst 33342 staining based microscopic analysis	[PMID: 34124675]
PC-3	IC₅₀	1.17 μM Compound: TPZ	Cytotoxicity against human PC3 cells for 72 hrs under hypoxic condition by MTT assay Cytotoxicity against human PC3 cells for 72 hrs under hypoxic condition by MTT assay	[PMID: 21281992]
PC-3	IC₅₀	20.97 μM Compound: TPZ	Cytotoxicity against human PC3 cells for 72 hrs under normoxic condition by MTT assay Cytotoxicity against human PC3 cells for 72 hrs under normoxic condition by MTT assay	[PMID: 21281992]
PC-3	IC₅₀	22.3 μM Compound: TPZ	Cytotoxicity against human PC3 cells after 48 hrs by MTT assay Cytotoxicity against human PC3 cells after 48 hrs by MTT assay	[PMID: 16777409]
SiHa	IC₅₀	2.5 μM Compound: 1, TPZ	Cytotoxicity against human SiHa cells under hypoxic conditions after 4 hrs Cytotoxicity against human SiHa cells under hypoxic conditions after 4 hrs	[PMID: 18001018]
SiHa	IC₅₀	2.5 μM Compound: 1, TPZ	Cytotoxicity against human SiHa cells after 4 hrs under strict hypoxic condition Cytotoxicity against human SiHa cells after 4 hrs under strict hypoxic condition	[PMID: 18847185]
SMMC-7721	IC₅₀	32.79 μM Compound: TPZ	Cytotoxicity against human SMMC7721 cells for 72 hrs under normoxic condition by MTT assay Cytotoxicity against human SMMC7721 cells for 72 hrs under normoxic condition by MTT assay	[PMID: 21281992]
SMMC-7721	IC₅₀	4.75 μM Compound: TPZ	Cytotoxicity against human SMMC7721 cells for 72 hrs under hypoxic condition by MTT assay Cytotoxicity against human SMMC7721 cells for 72 hrs under hypoxic condition by MTT assay	[PMID: 21281992]
SW-620	IC₅₀	1.2 μM Compound: Tirapazamine	Cytotoxicity against human SW620 cells incubated for 4 hrs under hypoxic condition followed by compound washout and measured after 5 days by SRB assay Cytotoxicity against human SW620 cells incubated for 4 hrs under hypoxic condition followed by compound washout and measured after 5 days by SRB assay	[PMID: 30885680]
SW-620	IC₅₀	91.03 μM Compound: Tirapazamine	Cytotoxicity against human SW620 cells incubated for 4 hrs under aerobic condition followed by compound washout and measured after 5 days by SRB assay Cytotoxicity against human SW620 cells incubated for 4 hrs under aerobic condition followed by compound washout and measured after 5 days by SRB assay	[PMID: 30885680]
U-251	IC₅₀	71.2 μg/mL Compound: TPZ	Growth inhibition of human U251 cells after 48 hrs by SRB assay Growth inhibition of human U251 cells after 48 hrs by SRB assay	[PMID: 20236735]
Vero	CC₅₀	8 μg/mL Compound: TPZ	Cytotoxicity against african green monkey Vero cells after 72 hrs by CellTiterGlo assay Cytotoxicity against african green monkey Vero cells after 72 hrs by CellTiterGlo assay	[PMID: 22691154]

体外研究
(In Vitro)

Tirapazamine (SR259075) is the optimal drug for combination therapy using Pba^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	SCC7 cells
Concentration:	1mg
Incubation Time:	24 h
Result:	Showed synergism with Pba at ED50, ED90 and ED95.

体内研究
(In Vivo)

Tirapazamine (SR259075) (1mg; intravenously injected; twice at a 24-h interval) shows a synergetic effect to kill tumor cells because TPZ was activated under the hypoxic conditions that originated from the PDT with Pba and laser irradiation^[1].
.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C3H/HeN mice^[1].
Dosage:	1mg
Administration:	Tirapazamine (1mg; intravenously injected; twice at a 24-h interval)
Result:	Suppressed the tumors of mice by using laser irradiation.

Clinical Trial

分子量

178.15

Formula

C₇H₆N₄O₂

CAS 号

27314-97-2

性状

固体

颜色

Orange to red

中文名称

替拉扎明

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

DMSO 中的溶解度 : 62.5 mg/mL (350.83 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	5.6132 mL	28.0662 mL	56.1325 mL
5 mM	1.1226 mL	5.6132 mL	11.2265 mL
10 mM	0.5613 mL	2.8066 mL	5.6132 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: 2.5 mg/mL (14.03 mM); 悬浊液; 超声助溶

此方案可获得 2.5 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
方案二

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (11.68 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案三

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (11.68 mM); 澄清溶液

此方案可获得 ≥ 2.08 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。

以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

方案一

请依序添加每种溶剂： 50% PEG300 50% Saline
Solubility: 10 mg/mL (56.13 mM); 悬浊液; 超声助溶

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.73%

选择批次：

Data Sheet (631 KB) SDS (393 KB)

COA (266 KB) LCMS (111 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Cai TY, et al. Tirapazamine sensitizes hepatocellular carcinoma cells to topoisomerase I inhibitors via cooperative modulation of hypoxia-inducible factor-1α. Mol Cancer Ther. 2014 Mar;13(3):630-42. [Content Brief]

[2]. Sliwinska J, et al. Tirapazamine-doxorubicin interaction referring to heart oxidative stress and Ca2? balance protein levels. Oxid Med Cell Longev. 2012;2012:890826. [Content Brief]

[3]. Lee, Donghyun, et al. Optimized Combination of Photodynamic Therapy and Chemotherapy Using Gelatin Nanoparticles Containing Tirapazamine and Pheophorbide a. ACS applied materials & interfaces vol. 13,9 (2021): 10812-10821. [Content Brief]

[4]. Romero, José, et al. Electronic structure and reactivity of tirapazamine as a radiosensitizer. Journal of molecular modeling vol. 27,6 177. 22 May. 2021. [Content Brief]

Tirapazamine 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	5.6132 mL	28.0662 mL	56.1325 mL	140.3312 mL
	5 mM	1.1226 mL	5.6132 mL	11.2265 mL	28.0662 mL
	10 mM	0.5613 mL	2.8066 mL	5.6132 mL	14.0331 mL
	15 mM	0.3742 mL	1.8711 mL	3.7422 mL	9.3554 mL
	20 mM	0.2807 mL	1.4033 mL	2.8066 mL	7.0166 mL
	25 mM	0.2245 mL	1.1226 mL	2.2453 mL	5.6132 mL
	30 mM	0.1871 mL	0.9355 mL	1.8711 mL	4.6777 mL
	40 mM	0.1403 mL	0.7017 mL	1.4033 mL	3.5083 mL
	50 mM	0.1123 mL	0.5613 mL	1.1226 mL	2.8066 mL
	60 mM	0.0936 mL	0.4678 mL	0.9355 mL	2.3389 mL
	80 mM	0.0702 mL	0.3508 mL	0.7017 mL	1.7541 mL
	100 mM	0.0561 mL	0.2807 mL	0.5613 mL	1.4033 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Tirapazamine (Synonyms: 替拉扎明; SR259075; SR4233; Win59075; SML 0552; SR 259075; Tirazone)

Customer Review

MCE 顾客使用本产品发表的 10 篇科研文献

Tirapazamine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Tirapazamine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Tirapazamine (Synonyms: 替拉扎明; SR259075; SR4233; Win59075; SML 0552; SR 259075; Tirazone)

Customer Review

Tirapazamine 相关抗体

MCE 顾客使用本产品发表的 10 篇科研文献

Tirapazamine 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

生物活性

纯度 & 产品资料

参考文献

Tirapazamine 相关抗体:

摩尔计算器

稀释计算器

Tirapazamine 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z